Mouse Tumor Biology Database (MTB)
MTB Home   Help
Search for Help
in these sections
Search Forms
Pathology Images
Search MTB Using Human Genes
Gene Expression Data Sets

Additional Resources
new PDX Like Me
PDX Finder
PDX Model Search
Faceted Tumor Search
Dynamic Tumor Frequency Grid
Other Cancer Websites
Lymphoma Pathology

Mouse Genome Informatics
The Jackson Laboratory
Citing These Resources
Warranty Disclaimer
& Copyright Notice

Send Questions and
Comments to User Support.

Last Database Update
MTB 3.0
HelpHelp and Documentation Reference Detail  
Title: Inhibitory effects of rebamipide on ENNG-induced duodenal carcinogenesis in mice: a possible strategy for chemoprevention of gastrointestinal cancers.
Authors: Yamane T; Nakatani H; Matsumoto H; Iwata Y; Kikuoka N; Takahashi T
Journal: Dig Dis Sci
Volume: 43
Issue: 9 Suppl
Year: 1998
Pages: 207S-211S
Abstract: Rebamipide is a potent antioxidative agent; it increases gastric mucosal PGE2 production and thus protects the gastric mucosa. We hypothesized that the mechanisms of ulcer formation could be extended to carcinogenesis and that an increase in gastric mucosal protection may result in a decrease in gastric carcinogenesis. Therefore, we assessed the inhibitory effects of rebamipide on N-ethyl-N'-nitro-N- nitrosoguanidine (ENNG) -induced carcinogenesis in mice. The percentage of tumor-bearing mice in three treatment groups--ENNG + rebamipide 20 mg, ENNG + rebamipide 50 mg, and ENNG alone--was 55%, 42%, and 67%, respectively. The incidence of tumorigenesis tended to decrease with increasing doses of rebamipide. The difference between ENNG + rebamipide 50 mg and ENNG alone was statistically significant (P < 0.05). These results suggest that rebamipide may strengthen the host defense mechanisms related to carcinogenesis in the digestive tract.
in MTB
Tumor Records (13)
Strains (1)
J:52691  Mouse Genome Informatics
9753252  National Library of Medicine/PubMed